| Literature DB >> 36160172 |
Yassin K Al Hariri1, Syed A S Sulaiman2,3, Amer H Khan2, Azreen S Adnan4, Sundos Q Al-Ebrahem1.
Abstract
Background: Leptospirosis is the most common anthropozoonosis worldwide and imposes a major public health problem in many tropical countries. It is a leading cause of disease burden in form of mortality, morbidity and hospital admission. Identifying patients at high risk for mortality or for prolonged hospitalization may save lives and preserve economy. The aim of the current study is to identify significant factors associated with disease mortality and prolonged hospitalization. Design: Cress-sectional retrospective study. Settings: Tertiary care teaching hospitals in Kelantan, Peninsular Malaysia. Participants: Adult patients proven to have leptospirosis depending on IgM ELISA were classified into two classes depending on prolonged hospitalization (>7 days or ≤ 7 days) and mortality (fatal cases or non-fatal cases). Patients' clinico-laboratory data were compared according to these two outcomes using the appropriate statistical test.Entities:
Keywords: Malaysia; leptospirosis; mortality; prediction; prolonged hospitalization
Year: 2022 PMID: 36160172 PMCID: PMC9500579 DOI: 10.3389/fmed.2022.887292
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Figure 1Study flow chart.
Comparison of demographics and clinical features (at baseline) between patients with and without prolonged hospitalization (>7 days).
|
| ||||
|---|---|---|---|---|
|
|
|
|
| |
| Age (years) | 38.10 ± 16.84 | 36.12 ± 15.946 | 43.79 ± 18.05 |
|
| Age >40 | 216 (41.1) | 140 (36.0) | 76 (55.9) |
|
| Age >60 | 62 (11.8) | 35 (9.0) | 27 (19.9) |
|
| Male gender | 344 (65.5) | 248 (63.8) | 96 (70.6) | 0.149 |
| Rural residence | 136 (25.9) | 81 (20.8) | 55 (40.4) |
|
| Leptospirosis risk group | 252 (48.0) | 195 (50.1) | 57 (41.9) | 0.099 |
| Severe leptospirosis | 303 (57.7) | 188 (48.3) | 115 (84.6) |
|
| Non-severe leptospirosis | 222 (42.3) | 201 (51.7) | 21 (15.4) | |
| Smoking | 117 (22.3) | 85 (21.9) | 32 (23.5) | 0.686 |
| Temperature (°c) | 37.84 ± 0.99 | 37.892 ± 1.03 | 37.677 ± 0.86 |
|
| Fever >38°c | 160 (30.5) | 128 (32.9) | 32 (23.5) |
|
| Fever >39 °c | 67 (12.8) | 57 (14.7) | 10 (7.4) |
|
| Pulse rate (BPM) | 99.71 ± 21.81 | 99.20 ± 21.75 | 101.17 ± 22 | 0.368 |
| Tachycardia | 240 (45.7) | 173 (44.5) | 67 (49.3) | 0.334 |
| Bradycardia | 7 (1.3) | 3 (0.8) | 4 (2.9) | 0.055 |
| RR | 22.07 ± 4.60 | 21.92 ± 4.23 | 22.52 ± 5.61 | 0.212 |
| Tachypnea RR >22 | 141 (26.9) | 103 (26.5) | 38 (27.9) | 0.740 |
| RR >28 | 44 (8.4) | 29 (7.5) | 15 (11.0) | 0.195 |
| SBP mmHg | 121.16 ± 21.66 | 122.30 ± 22.20 | 117.88 ± 19.74 |
|
| DBP mmHg | 72.82 ± 13.648 | 73.41 ± 13.82 | 71.13 ± 13.05 | 0.103 |
| Hypotension | 72 (13.7) | 50 (12.9) | 22 (16.2) | 0.332 |
| Shock | 49 (9.3) | 32 (8.2) | 17 (12.5) | 0.145 |
|
| ||||
| Cardiomegaly | 43 (8.2) | 26 (6.7) | 12 (8.8) | 0.133 |
| Pleural effusion | 26 (5) | 14 (3.6) | 12 (8.8) | 0.057 |
| Pulmonary edema | 6 (1.1) | 3 (0.8) | 3 (2.2) | 0.271 |
| Pulmonary infiltrate | 112 (21.3) | 81 (20.8) | 31 (22.8) | 0.062 |
| Respiratory failure | 13 (2.5%) | 10 (2.6) | 3 (2.2) | 1.00 |
|
| ||||
| T wave changes | 32 (6.1) | 22 (5.7) | 10 (7.4) | 0.930 |
| Atrial fibrillation | 14 (2.7) | 10 (2.6) | 4 (2.9) | 0.868 |
| Conduction abnormality | 13 (2.5) | 9 (2.3) | 4 (2.9) | 0.987 |
| Obesity | 4 (0.8) | 3 (0.8) | 1 (0.7) | 0.97 |
| Pregnancy | 17 (3.2) | 15 (3.9) | 2 (1.5) | 0.176 |
|
| ||||
| CKD | 23 (4.4) | 16 (4.1) | 7 (5.1) | 0.612 |
| DM | 70 (13.3) | 49 (12.6) | 21 (15.4) | 0.40 |
| HTN | 86 (16.4 | 60 (15.4) | 26 (19.1) | 0.316 |
| IHD | 10 (1.9) | 7 (1.8) | 3 (2.2) | 0.757 |
| CHF | 6 (1.1 | 5 (1.3) | 1 (0.7) | 0.608 |
| HPL | 14 (2.7) | 8 (2.1) | 6 (4.4) | 0.138 |
| Asthma | 11 (2.1) | 8 (2.1) | 3 (2.2) | 0.91 |
| Multiple comorbidities >1 | 60 (11.4) | 39 (10.0) | 21 (15.4) | 0.088 |
| Multiple comorbidities >2 | 17 (3.2) | 12 (3.1) | 5 (3.7) | 0.737 |
| MODs >1 | 153 (29.1) | 88 (22.6) | 65 (47.8) |
|
| MODs >2 | 53 (10.1) | 29 (7.5) | 24 (17.6) |
|
| Previous leptospirosis infection | 9 (1.7) | 8 (2.1) | 1 (0.7) | 0.303 |
| Concomitant dengue | 37 (7) | 28 (7.2) | 9 (6.6) | 0.820 |
| Pneumonia | 85 (16.2) | 49 (12.6) | 36 (26.5) |
|
| Sepsis | 44 (8.4) | 23 (5.9) | 21 (15.4) |
|
| Days before hospitalization | 5.18 ± 4.2 | 4.90 ± 3.58 | 5.98 ± 5.42) |
|
| Late hospitalization >4 d | 258 (49.1) | 185 (47.6) | 73 (53.7) | 0.219 |
| LOS (days) | 6.77 ± 5.68 | 4.46 ±1.53 | 13.34 ± 7.7 |
|
| Duration before AB use | 6.13 ± 5.18 | 5.67 ±3.55 | 7.43 ± 8.10 |
|
| Delayed AB use >2 d | 464 (88.4) | 339 (87.1) | 125 (91.9) | 0.136 |
| Delayed AB use >3 days | 370 (70.5) | 262 (67.4) | 108 (79.4) |
|
| ICU admission | 83 (15.8%) | 53 (13.7) | 30 (22.1) |
|
| Death | 34 (6.5) | 24 (6.2) | 10 (7.4) | 0.629 |
RR, respiratory rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; IHD, ischemic heart disease; CHF, congestive heart failure; HPL, hyperlipidemia; LOS, length of stay; MODs, multiple organ dysfunctions. *P-values were calculated between patients with and without prolonged hospitalization. The bold values indicate statistically significant p-values.
Comparison of clinical manifestation (at baseline) between leptospirosis patients with and without prolonged hospitalization.
|
|
|
|
| |
|---|---|---|---|---|
|
| ||||
| Fever | 492 (93.7) | 369 (94.9) | 123 (90.4) | 0.068 |
| Myalgia | 345 (65.7) | 268 (68.9) | 77 (56.6) | 0.009 |
| N & V | 321 (61.1) | 245 (63.0) | 76 (55.9) | 0.144 |
| Arthralgia | 284 (54.1) | 219 (56.3) | 65 (47.8) | 0.096 |
| Headache | 253(48.2) | 206 (53.0) | 47 (34.6) | <0.001 |
| chills | 241 (45.9) | 181 (46.5) | 60 (44.1) | 0.627 |
| Lethargy | 213 (40.6) | 148 (38.0) | 65 (47.8) |
|
| Abdominal pain | 202 (38.5) | 142 (36.5) | 60 (44.1) | 0.121 |
| Diarrhea | 197 (37.5) | 155 (39.8) | 42 (30.9) | 0.063 |
| Cough | 181 (34.5) | 129 (33.2) | 52 (38.2) | 0.284 |
|
| ||||
| Dehydration | 141 (26.9) | 96 (24.7) | 45 (33.1) | 0.057 |
| Hemorrhagic diathesis | 95 (18.1) | 59 (15.2) | 36 (26.5) |
|
| Hepatomegaly | 89 (17.0) | 55 (14.1) | 34 (25.0) |
|
| Dyspnea | 87 (16.6) | 57 (14.7) | 30 (22.1) |
|
| Anorexia | 63 (12.0) | 38 (9.8) | 25 (18.4) |
|
| Conjunctival suffusion | 42 (8.0) | 30 (7.7) | 12 (8.8) | 0.704 |
| Dizziness | 36 (6.9) | 25 (6.4) | 11 (8.1) | 0.496 |
| Retro-orbital pain | 33 (6.3) | 32 (8.2) | 1 (0.7) |
|
| Malaise | 32 (6.1) | 17 (4.4) | 15 (11.0) |
|
| Pulmonary rales | 23 (4.4) | 10 (2.6) | 13 (9.6) |
|
| Pulmonary hemorrhage | 18 (3.4) | 12 (3.1) | 6 (4.4) | 0.426 |
| Sore throat | 16 (3.0) | 14 (3.6) | 2 (1.5) | 0.148 |
| Hematuria | 16 (3.0) | 6 (1.5) | 10 (7.4) |
|
| Disturbed consciousness | 15 (2.9) | 8 (2.1) | 7 (5.1) | 0.063 |
| Petechia purpura ecchymosis | 15 (2.9) | 10 (2.6) | 5 (3.7) | 0.515 |
| Chest pain | 12 (2.3) | 12 (3.1) | 0 (0) | 0.027 |
| Hemoptysis | 10 (1.9) | 7 (1.8) | 3 (2.2) | 0.774 |
| convulsion | 7 (1.3) | 4 (1.0) | 3 (2.2) | 0.303 |
| Splenomegaly | 6 (1.1) | 3 (0.8) | 3 (2.2) | 0.175 |
| Gingivorrhagia | 6 (1.1) | 4 (1.0) | 2 (1.5) | 0.683 |
| Malena | 6 (1.1) | 4 (1.0) | 2 (1.5) | 0.683 |
| Hematemesis | 4 (0.8) | 1 (0.3) | 3 (2.2) |
|
| Flapping | 2 (0.4) | 2 (0.5) | 0 (0) | 0.402 |
| Paraparesis | 1 (0.2) | 0 (0) | 1 (0.7) | 0.09 |
N & V, nausea and vomiting. *P-values were calculated between leptospirosis patients with and without prolonged hospitalization. The bold values indicate statistically significant p-values.
Comparison of clinico-laboratory characteristics (at baseline) between patients with and without prolonged hospitalization.
|
|
|
|
| |
|---|---|---|---|---|
| Na (mmol/L) | 133.70 ± 5.75 | 133.82 ± 5.30 | 133.33 ± 6.88 | 0.391 |
| K (mmol/L) | 3.841 ± 0.63 | 3.79 ± 0.59 | 3.98 ± 0.74 |
|
| Urea (mmol/L) | 10.13 ± 11.78 | 8.05 ± 8.76 | 16.07 ± 16.44 |
|
| Scr (μmol/L) | 184.51 ± 219.80 | 149.33 ± 157.68 | 285.15 ± 319.84 |
|
| Uric Acid (μmol/L) | 418.94 ± 206.48 | 376.82 ± 159.134 | 491.28 ± 255.19 |
|
| AST (IU/L) | 117.72 ± 337.02 | 93.41 ± 247.782 | 189.66 ± 512.65 |
|
| ALT (IU/L) | 114.84 ± 401.49 | 106.79 ± 432.570 | 138.50 ± 291.78 | 0.439 |
| ALP (IU/L) | 135.85 ± 99.02 | 129.52 ± 103.05 | 154.49 ± 83.70 |
|
| Total Protein (g/L) | 68.71 ± 9.65 | 69.59 ± 9.39 | 66.10 ± 9.98 |
|
| Albumin (g/L) | 36.06 ± 6.71 | 36.96 ± 6.62 | 33.39 ± 6.26 |
|
| Globulin (g/L) | 32.78 ± 6.47 | 32.81 ± 6.27 | 32.71 ± 7.05 | 0.876 |
| Albumin/Globulin ratio | 1.17 ± 0.3 | 1.19 ± 0.28 | 1.13 ± 0.33 | 0.054 |
| Total bilirubin (μmol/L) | 36.327 ± 66.58 | 26.56 ± 43.50 | 64.43 ± 103.69 |
|
| WBCs (cells × 109) | 12.82 ± 13.37 | 12.76 ± 14.74 | 12.99 ± 8.45 | 0.866 |
| RBCs (cells × 1012) | 4.684 ± 0.86 | 4.81 ± 0.84 | 4.35 ± 0.88 |
|
| PLT (cells × 109) | 179.98 ± 111.14 | 191.46 ± 110.56 | 147.92 ± 106.74 |
|
| Hemoglobin (g/dl) | 13.668 ± 8.72 | 14.2 ± 10.01 | 12.19 ± 2.31 |
|
| Hematocrit (%) | 38.16 ± 7.34 | 39.01 ± 6.88 | 35.78 ± 8.03 |
|
| PT (s) | 13.72 ± 3.32 | 13.53 ±3.45 | 14.19 ± 2.93 | 0.097 |
| APTT (s) | 38.38 ± 9.47 | 38.81 ± 9.58 | 37.4 ± 9.18 | 0.199 |
| INR | 1.22 ± 0.31 | 1.214 ± 0.32 | 1.24 ± 0.28 | 0.399 |
| CRP (mg/dl) | 26.02 ± 48.3 | 23.19 ± 45.92 | 34.90 ± 54.49 | 0.071 |
| Venous PH | 7.39 ± 0.22 | 7.39 ± 0.25 | 7.39 ± 0.09 | 0.954 |
|
| ||||
| Hyponatremia | 94 (17.9) | 61 (15.7) | 33 (24.3) |
|
| Hypokalemia | 141 (26.9) | 110 (28.3) | 31 (22.8) | 0.214 |
| Hyperkalemia | 27 (5.1) | 13 (3.3) | 14 (10.3) |
|
| Hyperuricemia >420 μmol/L | 52 (9.9) | 25 (6.4) | 27 (19.9) |
|
| AKI admission | 238 (45.3) | 146 (37.5) | 92 (67.6) |
|
| Elevated ALT | 74 (14.1) | 45 (11.6) | 29 (21.3) |
|
| Elevated AST | 77 (14.7) | 49 (12.6) | 28 (20.6) |
|
| Elevated ALP | 48 (9.1) | 32 (8.2) | 16 (11.8) | 0.181 |
| Transaminitis | 52 (9.9) | 31 (8.0) | 21 (15.4) |
|
| Jaundice | 77 (14.7) | 38 (9.8) | 39 (28.7) |
|
| Hypoalbuminemia <34 g/L | 203 (38.7) | 128 (32.9) | 75 (55.1) |
|
| Urinary sedimentations | 109 (20.8) | 80 (20.6) | 29 (21.3) | 0.851 |
| Rhabdomyolysis | 40 (7.6) | 23 (5.9) | 17 (12.5) |
|
| Leukocytosis | 224 (42.7) | 154 (39.6) | 70 (51.5) |
|
| Leucopenia | 36 (6.9) | 29 (7.5) | 7 (5.1) | 0.359 |
| Thrombocytopenia | 233 (44.4) | 155 (39.8) | 78 (57.4) |
|
| Low RBC counts | 72 (13.7) | 37 (9.5) | 35 (25.7) |
|
| Low hemoglobin | 111 (21.1) | 59 (15.2) | 52 (38.2) |
|
| Prolonged PT | 179 (34.1) | 113 (29.0) | 66 (48.5) |
|
| Prolonged aPTT | 44 (8.4) | 34 (8.7) | 10 (7.4) | 0.615 |
| Prolonged aPTT and PT | 35 (6.7) | 27 (6.9) | 8 (5.9) | 0.670 |
| Low venous PH | 35 (6.7) | 21 (5.4) | 14 (10.3) | 0.051 |
Na, sodium; K, potassium; BUN, blood urea nitrogen; Scr, serum creatinine; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; CK, creatinine kinase; WBCs, white blood cells; RBCs, red blood cells; PLT, platelets; PT, prothrombin time; aPTT, activated partial thromboplastin time; INR, international normalized ratio; CRP, C reactive protein. *P-values were calculated between patients with and without prolonged hospitalization. The bold values indicate statistically significant p-values.
Univariate and multivariate logistic regression analysis to determine the predictors (risk factors) for prolonged hospitalization of leptospirosis.
|
|
|
| ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| Age >40 | <0.001 | 2.3 | 1.5–3.4 | 0.479 | 0.81 | 0.5–1.4 |
| Male gender | 0.150 | 1.4 | 0.89–2.1 | 0.124 | 1.5 | 0.9–2.6 |
| Late hospitalization | 0.220 | 1.3 | 0.9–1.9 | 0.979 | 0.99 | 0.6–1.7 |
| Pulmonary rales | 0.001 | 4.0 | 1.7–9.4 | 0.153 | 2.3 | 0.7–6.9 |
| AKI | <0.001 | 3.5 | 2.3–5.3 |
| 2.3 | 1.3–4.1 |
| Jaundice | <0.000 | 3.9 | 2.3–6.4 |
| 2.7 | 1.4–5.0 |
| Elevated ALT | 0.006 | 2.1 | 1.2–3.5 |
| 2.0 | 0.99–4.1 |
| Low RBCs | <0.000 | 3.1 | 1.9–5.4 | 0.074 | 1.8 | 0.95–3.3 |
| Prolonged PT | <0.000 | 2.3 | 1.5–3.4 |
| 1.9 | 1.1–3.2 |
AKI, acute kidney injury; ALT, alanine aminotransferase; RBCs, red blood cells; PT, prothrombin time. Odd ratios (OR) and confidence intervals (CI) have been rounded off. Hosmer and Lemeshow Test Chi square value = 11.87, Degree of freedom = 8, P = 0.157. The bold values indicate statistically significant p-values.
Figure 2Receiver operating characteristic (ROC) curve analysis of predictor for risk factors logistic regression model to predict prolong hospitalization of leptospirosis.
Comparison of demographics and clinical characters (at baseline) between fatal and non-fatal leptospirosis cases.
|
|
|
|
| |
|---|---|---|---|---|
| Age (Years) | 38.10 ± 16.84 | 37.35 ± 16.602 | 48.97 ± 16.727 |
|
| Age >40 | 216 (41.1) | 192 (39.1) | 24 (70.6) |
|
| Age >60 | 62 (11.8) | 52 (10.6) | 10 (29.4) |
|
| Male gender | 344 (65.5) | 324 (66.0) | 20 (58.8) | 0.395 |
| Female gender | 181 (34.5) | 167 (34.0) | 14 (41.2) | |
| Rural residence | 136 (25.9) | 133 (27.1) | 3 (8.8) |
|
| Leptospirosis risk group | 252 (48.0) | 241 (49.1) | 11 (32.4) | 0.059 |
| Smoking | 117 (22.3) | 107 (21.8) | 10 (29.4) | 0.302 |
| Temperature (°c) | 37.8 ± 0.99 | 37.85 ± 0.99 | 37.6 ± 1.0 | 0.157 |
| Temperature >38°c | 160 (30.5) | 153 (31.2) | 7 (20.6) | 0.195 |
| Tachypnea RR >22 | 141 (26.9) | 124 (25.3) | 17 (50.0) |
|
| RR >28 | 44 (8.4) | 34 (6.9) | 10 (29.4) |
|
| Pulse rate (BPM) | 99.71 ± 21.81 | 98.72 ± 21.10 | 113.85 ± 26.84 | <0.001 |
| Tachycardia | 240 (45.7) | 219 (44.6) | 21 (61.8) | 0.052 |
| SBP mmHg | 121.2 ± 21.7 | 122.29 ± 1.131 | 104.85 ± 2.957 |
|
| DBP mmHg | 72.82 ± 13.6 | 73.11 ± 13.207 | 67.54 ± 19.666 |
|
| Hypotension | 72 (13.7) | 64 (13.0) | 8 (23.5) | 0.116 |
| Shock needed inotropes | 49 (9.3) | 32 (6.5) | 17 (50) |
|
| Pulmonary Infiltrate | 112 (21.3) | 93 (18.9) | 19 (55.9) |
|
|
| ||||
| T wave changes | 32 (6.1) | 22 (4.5) | 10 (29.4) |
|
| Atrial fibrillation | 14 (2.7) | 10 (2.0) | 4 (11.8) |
|
| Conduction abnormality | 13 (2.5) | 7 (1.4) | 6 (17.6) |
|
| Obesity | 4 (0.8) | 4 (0.8) | 0 (0) | 1 |
| Pregnancy | 17 (3.2) | 16 (3.3) | 1 (2.9) | 1 |
|
| ||||
| CKD | 23 (4.4) | 16 (3.3) | 7 (20.6) |
|
| DM | 70 (13.3) | 66 (13.4) | 4 (11.8) | 1 |
| HTN | 86 (16.4 | 81 (16.5) | 5 (14.7) | 0.785 |
| IHD | 10 (1.9) | 10 (2.0) | 0 | 1 |
| CHF | 6 (1.1) | 6 (1.2) | 0 | 1 |
| HPL | 14 (2.7) | 14 (2.9) | 0 | 1 |
| Asthma | 11 (2.1) | 11 (2.2) | 0 | 1 |
| Multiple comorbidities | 60 (11.4) | 55 (11.2) | 5 (14.7) | 0.574 |
| Resp Failure needed MV | 13 (2.5) | 9 (1.8) | 4 (11.8) |
|
| Dialysis needed | 42 (8) | 26 (5.3) | 16 (47.1) |
|
| MODs >1 | 153 (29.1) | 125 (25.5) | 28 (82.4) |
|
| Hyponatremia | 94 (17.9) | 87 (17.7) | 7 (20.6) | 0.673 |
| K (mmol/L) | 3.841 ± 0.63 | 3.819 ± 0.6265 | 4.151 ± 0.7328 |
|
| Hyperkalemia | 27 (5.1) | 23 (4.7) | 4 (11.8) | 0.089 |
| AKI | 238 (45.3) | 210 (42.8) | 28 (82.4) |
|
| Elevated ALT | 74 (14.1) | 63 (12.8) | 11 (32.4) |
|
| Elevated AST | 77 (14.7) | 63 (12.8) | 14 (41.2) |
|
| AST/ALT Ratio | 1.4 ± 1.72 | 1.37 ± 1.75 | 1.82 ± 1.23 |
|
| Elevated ALP | 48 (9.1) | 44 (9.0) | 4 (11.8) | 0.531 |
| Jaundice | 77 (14.7) | 68 (13.8) | 9 (26.5) | 0.053 |
| Hypoalbuminemia | 203 (38.7) | 180 (36.7) | 23 (67.6) |
|
| Rhabdomyolysis | 40 (7.6) | 29 (5.9) | 11 (32.4) |
|
| Leukocytosis | 224 (42.7) | 206 (42.0) | 18 (52.9) | 0.210 |
| Thrombocytopenia | 233 (44.4) | 218 (44.4) | 15 (44.1) | 0.975 |
| Severe thrombocytopenia | 59 (11.2) | 51 (10.4) | 8 (23.5) |
|
| Anemia | 111 (21.1) | 101 (20.6) | 10 (29.4) | 0.166 |
| Prolonged PT | 179 (34.1) | 157 (32.0) | 22 (64.7) |
|
| Prolonged aPTT | 44 (8.4) | 37 (7.5) | 7 (20.6) |
|
| Low venous PH | 35 (6.7) | 31 (6.3) | 4 (11.8) |
|
| Concomitant dengue | 37 (7) | 34 (6.9) | 3 (8.8) | 0.676 |
| Pneumonia | 85 (16.2) | 68 (13.8) | 17 (50.0) |
|
| Sepsis | 44 (8.4) | 36 (7.3) | 8 (23.5) |
|
| Late hospitalization | 258 (49.1) | 241 (49.1) | 17 (50.0) | 0.918 |
| LOS (days) | 6.77 ± 5.68 | 6.61 ± 5.07 | 9.12 ± 11.12 | 0.516 |
| Delayed AB use: | 464 (88.4) | 431 (87.8) | 33 (97.1) | 0.161 |
| ICU admission | 83 (15.8) | 62 (12.6) | 21 (61.8) |
|
RR, respiratory rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension; IHD, ischemic heart disease; CHF, congestive heart failure; HPL, hyperlipidemia; MV, mechanical ventilation; LOS, length of stay; MODs, multiple organ dysfunctions. *P-values were calculated between fatal and non-fatal cases. The bold values indicate statistically significant p-values.
Comparison of clinical manifestation (at baseline) between fatal and non-fatal leptospirosis patients.
|
|
|
|
| |
|---|---|---|---|---|
| Fever | 492 (93.7) | 466 (94.9) | 26 (76.5) |
|
| Myalgia | 345 (65.7) | 333 (67.8) | 12 (35.3) |
|
| N & V | 321 (61.1) | 302 (61.5) | 19 (55.9) | 0.515 |
| Arthralgia | 284 (54.1) | 275 (56.0) | 9 (26.5) |
|
| Headache | 253(48.2) | 245 (49.9) | 8 (23.5) |
|
| chills | 241 (45.9) | 235 (47.9) | 6 (17.6) |
|
| Lethargy | 213 (40.6) | 191 (38.9) | 22 (64.7) |
|
| Abdominal pain | 202 (38.5) | 192 (39.1) | 10 (29.4) | 0.258 |
| Diarrhea | 197 (37.5) | 191 (38.9) | 6 (17.6) |
|
| Cough | 181 (34.5) | 166 (33.8) | 15 (44.1) | 0.221 |
| Dehydration | 141 (26.9) | 128 (26.1) | 13 (38.2) | 0.122 |
|
| ||||
| Hemorrhagic diathesis | 95 (18.1) | 86 (17.5) | 9 (26.5) | 0.19 |
| Hepatomegaly | 89 (17.0) | 80 (16.3) | 9 (26.5) | 0.126 |
| Dyspnea | 87 (16.6) | 72 (14.7) | 15 (44.1) |
|
| Anorexia | 63 (12.0) | 61 (12.4) | 2 (5.9) | 0.41 |
| Conjunctival suffusion | 42 (8.0) | 40 (8.1) | 2(5.9) | 1 |
| Dizziness | 36 (6.9) | 35 (7.1) | 1 (2.9) | 0.5 |
| Retro-orbital pain | 33 (6.3) | 33 (6.7) | 0 (0) | 0.382 |
| Malaise | 32 (6.1) | 31 (6.3) | 1 (2.9) | 0.712 |
| Pulmonary rales | 23 (4.4) | 19 (3.9) | 4 (11.8) |
|
| Pulmonary hemorrhage | 18 (3.4) | 14 (2.9) | 4 (11.8) |
|
| Sore throat | 16 (3.0) | 14 (2.9) | 2 (5.9) | 0.169 |
| Hematuria | 16 (3.0) | 15 (3.1) | 1 (2.9) | 1 |
| Disturbed consciousness | 15 (2.9) | 12 (2.4) | 3 (8.8) | 0.066 |
| Petechia purpura ecchymosis | 15 (2.9) | 15 (3.1) | 0 (0) | 0.614 |
| Chest pain | 12 (2.3) | 11 (2.2) | 1 (2.9) | 0.428 |
| Hemoptysis | 10 (1.9) | 9 (1.8) | 1 (2.9) | 0.493 |
| Convulsion | 7 (1.3) | 5 (1.0) | 2 (5.9) | 0.07 |
| Splenomegaly | 6 (1.1) | 6 (1.2) | 0 (0) | 1 |
| Gingivorrhagia | 6 (1.1) | 5 (1.0) | 1 (2.9) | 0.334 |
| Malena | 6 (1.1) | 5 (1.0) | 1(2.9) | 0.334 |
| Encephalitis | 4 (0.8) | 3 (0.6) | 1 (2.9) | 0.236 |
N & V, nausea and vomiting. *P-values were calculated between fatal and non-fatal leptospirosis patients. The bold values indicate statistically significant p-values.